Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
HIV Med ; 11(1): 40-5, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19686438

RESUMEN

BACKGROUND: Atazanavir (ATV) has demonstrated high efficacy and safety in both treatment-naïve and treatment-experienced patients. Some comparative data are available on the durability of ritonavir-boosted (ATV/r) and unboosted formulations, but there are no data on clinicians' motivations for choosing one or another in everyday practice. The aim of this study was to evaluate the long-term efficacy of boosted and unboosted ATV in a cohort of treatment-experienced patients. METHODS: All patients included in the study were enrolled in an observational cohort within the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) Project. Data on CD4 cell count, HIV viral load, metabolic parameters and adverse events of grade 3-4 are collected through an on-line system every six months. The duration of treatment with ATV was evaluated using the Kaplan-Meier curve and boosted and unboosted regimens were compared using the log-rank test. RESULTS: A total of 509 patients starting ATV as a component of their antiretroviral therapy were enrolled in the SCOLTA Project at the time of the study. Boosted ATV was received by 379 patients (74.5%) while 130 (25.5%) were treated with the unboosted formulation. The last therapeutic regimen did not influence the choice of ATV formulation. The mean observational time was 23.9 months. At the end of follow-up, 58.5% of patients on unboosted ATV and 58.1% of patients on ATV/r continued the treatment and no statistically significant differences were observed for ATV durability between the formulations or among the single causes of therapy interruption. CONCLUSIONS: Our results suggest that, in unselected clinical settings, ATV-containing antiretroviral therapy is durable and safe in both its formulations.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/uso terapéutico , Oligopéptidos/uso terapéutico , Piridinas/uso terapéutico , Ritonavir/uso terapéutico , Adenina/análogos & derivados , Adenina/uso terapéutico , Adulto , Fármacos Anti-VIH/efectos adversos , Terapia Antirretroviral Altamente Activa/métodos , Sulfato de Atazanavir , Recuento de Linfocito CD4 , Estudios de Cohortes , Esquema de Medicación , Interacciones Farmacológicas , Femenino , Inhibidores de la Proteasa del VIH/efectos adversos , Humanos , Estimación de Kaplan-Meier , Masculino , Oligopéptidos/efectos adversos , Organofosfonatos/uso terapéutico , Piridinas/efectos adversos , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Ritonavir/efectos adversos , Tenofovir , Resultado del Tratamiento , Carga Viral
2.
HIV Med ; 10(7): 422-31, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19459995

RESUMEN

BACKGROUND: We hypothesized that there may be a correlation between the interleukin-7 (IL-7)/IL-7 receptor (IL-7R) regulatory system and parameters of T-cell homeostasis in HIV-infected long-term nonprogressors (LTNPs) as compared with patients with disease progression. METHODS: The possibility of a correlation between T-cell homeostatic parameters and IL-7/IL-7R was investigated in 22 LTNPs (CD4 count > or =500 cells/microL for >10 years) vs. HIV-positive patients at different disease stages [12 early: CD4 count > or =400 cells/microL ; 15 late (AIDS-presenters): CD4 count < or =150 cells/microL ]. RESULTS: Compared with early-stage HIV-positive patients, LTNPs displayed a higher circulating IL-7 concentration (P=0.05), which was positively associated with higher IL-7Ralpha expression and a higher T-cell receptor excision circle (TREC) content specifically within CD4 cells (P<0.05). Compared with late-stage disease patients, early-stage disease patients displayed a lower IL-7 concentration (P<0.01) and higher percentages of IL-7Ralpha+ CD4 and CD8 cells (P=0.05). IL-7 was positively correlated with the percentage of TREC+ CD4 cells (P<0.01), which translated into a higher percentage of naïve CD4 cells in early-stage disease patients than in late-stage disease patients; however, the CD4 cells in early-stage disease patients were less enriched in recent thymic emigrants (RTEs) compared with LTNPs (P<0.05). In late-stage AIDS-developing patients, substantially increased IL-7 was correlated with a decreased percentage of IL-7Ralpha+ CD4 cells (P=0.01), which resulted in these patients having a significantly lower percentage of naïve T cells (P<0.01) and a significantly lower content of TREC (P<0.01) than the other patients. CONCLUSIONS: The maintenance of high CD4 cell counts in LTNPs was associated with a specific IL-7/IL-7R pattern characterized by increased IL-7 and highest IL-7Ralpha-expressing CD4 cells relative to other patients. Compared with patients with late-stage disease, LTNPs displayed a phenotypically naïve, less activated CD4 cell pool highly enriched in RTEs, suggesting the existence of a compensatory IL-7-mediated pathway specifically sustaining peripheral CD4 counts.


Asunto(s)
Infecciones por VIH/sangre , Sobrevivientes de VIH a Largo Plazo , Homeostasis , Interleucina-7/sangre , Receptores de Interleucina-7/sangre , Linfocitos T/inmunología , Adulto , Anciano , Recuento de Linfocito CD4 , Estudios Transversales , Regulación hacia Abajo , Femenino , Reordenamiento Génico de Linfocito T , Infecciones por VIH/inmunología , Homeostasis/inmunología , Humanos , Interleucina-7/inmunología , Antígeno Ki-67/metabolismo , Activación de Linfocitos/inmunología , Masculino , Persona de Mediana Edad , Receptores de Interleucina-7/inmunología , Linfocitos T/metabolismo , Timo/citología
3.
Clin Microbiol Infect ; 11(5): 343-6, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15819858

RESUMEN

Analysis of the literature on cutaneous leishmaniasis in low-prevalence countries suggests an increase in imported cases that is attributable to the growing phenomenon of international tourism, migration and military operations in highly endemic regions. Cases of imported cutaneous leishmaniasis are often missed initially, but diagnosis can be made non-invasively by PCR using skin scrapings of lesions as starting material. Cutaneous leishmaniasis is an emerging threat for travellers and should be considered in all patients presenting with slow-to-heal ulcers.


Asunto(s)
Leishmania , Leishmaniasis Cutánea/epidemiología , Viaje , Animales , Emigración e Inmigración , Salud Global , Humanos , Leishmania/genética , Leishmania/aislamiento & purificación , Leishmaniasis Cutánea/diagnóstico , Personal Militar , Reacción en Cadena de la Polimerasa , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA